SCHEMBL613441

SCHEMBL613441

CCC[C]1C=CC=CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL613449 0.86 DAO (0.34)
SCHEMBL614533 0.84 ACHE (0.37)
SCHEMBL1071912 0.79
SCHEMBL1071429 0.76 FFAR1 (0.31)
SCHEMBL8681375 0.76
SCHEMBL27487958 0.72
SCHEMBL1070233 0.70
SCHEMBL18378580 0.69
SCHEMBL1071782 0.69
SCHEMBL1071593 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024099911-A1 IRON CARBONYL COMPLEXES WITH CHIRAL, BIDENTATE BIPHOSPHINE LIGANDS BASF SE (DE) 2024-05-16 WO disclosed
EP-4269119-A1 COLOR DEVELOPER, HEAT-SENSITIVE RECORDING MATERIAL, AND COATING MATERIAL FOR HEAT-SENSITIVE RECORDING LAYERS Sanko Co., Ltd. (JP) 2023-11-01 EP disclosed
WO-2023137133-A2 PROCESS FOR THE SELECTIVE CATALYTIC HYDROGENATION OF DIENONES BASF SE (DE) 2023-07-20 WO disclosed
US-RE49036-E1 Method for synthesizing optically active carbonyl compounds BASF SE (DE) 2022-04-19 US disclosed
CN-113905734-A Novel compound and composition for preventing or treating respiratory diseases comprising the same as active ingredient 延世大学校产学协力团 2022-01-07 CN disclosed
EP-3342599-B1 HEAT-SENSITIVE RECORDING MATERIAL SANKO CO LTD (JP) 2021-06-16 EP disclosed
CN-107250091-B Method for synthesizing optically active carbonyl compound 巴斯夫欧洲公司 2021-05-04 CN disclosed
EP-3489213-B1 COMPOSITION FOR USE IN A METHOD FOR THE PREPARATION OF OPTICALLY ACTIVE CARBONYL COMPOUNDS BASF SE (DE) 2021-04-28 EP disclosed
EP-3489213-A1 COMPOSITION FOR USE IN A METHOD FOR THE PREPARATION OF OPTICALLY ACTIVE CARBONYL COMPOUNDS BASF SE (DE) 2019-05-29 EP disclosed
US-10301244-B2 Method for synthesizing optically active carbonyl compounds BASF SE (DE) 2019-05-28 US disclosed
US-6590071-B1 Increasing the delivery of hydrophilic amine containing compounds to the cell having a mucosal barrier, in which a compound of given formula penetrates the mucosal barrier of the cell; free amine is liberated by hydrolysis UNIVERSITY OF SOUTHERN CALIFORNIA 2003-07-08 US disclosed
WO-2003027637-A2 ASSESSMENT OF NEURONS IN THE ARCUATE NUCLEUS TO SCREEN FOR AGENTS THAT MODIFY FEEDING BEHAVIOR OREGON HEALTH AND SCIENCE UNIVERSITY (US) 2003-04-03 WO disclosed
WO-2003026591-A2 MODIFICATION OF FEEDING BEHAVIOR IMPERIAL COLLEGE INNOVATIONS LTD. (GB) 2003-04-03 WO disclosed
EP-1137631-A1 REVERSIBLE AQUEOUS pH SENSITIVE LIPIDIZING REAGENTS, COMPOSITIONS AND METHODS OF USE UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2001-10-04 EP disclosed
WO-2000034236-A1 REVERSIBLE AQUEOUS pH SENSITIVE LIPIDIZING REAGENTS, COMPOSITIONS AND METHODS OF USE UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2000-06-15 WO disclosed
US-5480761-A CHROMOGENIC PHOTOGRAPHIC ELEMENTS WITH DIFFUSION TRANSFER EASTMAN KODAK COMPANY (US) 1996-01-02 US disclosed
US-5468587-A Water developable chromogenic photographic heat transferable non-aqueous dye diffusion transfer photographic element EASTMAN KODAK COMPANY (US) 1995-11-21 US disclosed
EP-0546164-A1 INDOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS FIDIA RESEARCH FOUNDATION (US) 1993-06-16 EP disclosed
US-5206382-A INDOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS FIDIA GEORGETOWN INSTITUTE FOR THE NEUROSCIENCES (US) 1993-04-27 US disclosed
WO-1993000334-A1 INDOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS FIDIA - GEORGETOWN INSTITUTE FOR THE NEUROSCIENCES (US) 1993-01-07 WO disclosed